A Study of APTO-253 HCl in Patients With Relapsed or Refractory Hematologic Malignancies

Overview

This is a phase 1b study to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and recommended phase 2 dose of APTO-253 HCl in patients with relapsed or refractory hematologic malignancies.

SparkCures ID 659
Trial Phase Phase 1
Enrollment 60 Patients
Treatments
  • APTO-253
Trial Sponsors
  • Aptose Biosciences
NCT Identifier

NCT02267863

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Male or female 18 years of age or older
  • Histologically or cytologically proven diagnosis of hematologic malignancies for whom all standard therapy options have failed
  • Meet laboratory parameter requirements at study entry

Exclusion Criteria:

  • Pregnancy or breast feeding
  • History of prior malignancy
  • Auto-immune hemolytic anemia
  • Acute Promyelocytic Leukemia
  • Uncontrolled and clinically significant disease-related metabolic disorder
  • Other serious illness or medical conditions
  • Patients who have exhibited allergic reactions to compounds structurally similar to APTO-253 HCl

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

Verified Winship Cancer Institute of Emory University<br />

SparkCures Verified Accurate, up-to-date information. Learn more


Ochsner Foundation Clinic

Jefferson, LA

University of Rochester Medical Center
James P. Wilmot Cancer Center

Rochester, NY

Not Currently Accepting Patients

The following is a listing of trial locations that are not currently open and accepting patients.

California
Georgia
Verified Winship Cancer Institute of Emory University<br />

SparkCures Verified Accurate, up-to-date information. Learn more

Louisiana
Ochsner Foundation Clinic

Jefferson, LA

Michigan
New York
University of Rochester Medical Center
James P. Wilmot Cancer Center

Rochester, NY

Texas

Resources

There are no resources, links or videos to display for this clinical trial.